47 results
8-K
EX-99.1
PRAX
Praxis Precision Medicines Inc
13 May 24
Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2024 Financial Results
8:18am
, partially offset by $2.4 million in decreased expenses related to the Company’s Solidus™ platform.
General and administrative expenses were $15.3 million … and administrative expenses of approximately $2.0 million was primarily due to an increase in personnel-related costs, partially offset by a decrease in consulting
424B5
PRAX
Praxis Precision Medicines Inc
29 Mar 24
Prospectus supplement for primary offering
4:29pm
taxable disposition of our common stock or pre-funded warrants, which may be offset by U.S. source capital losses of the non-U.S. holder (even though
424B5
PRAX
Praxis Precision Medicines Inc
27 Mar 24
Prospectus supplement for primary offering
4:49pm
, which may be offset by U.S. source capital losses of the non-U.S. holder (even though the individual is not considered a resident of the United States
8-K
EX-99.1
bfvjexcgnv9br2p
5 Mar 24
Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
7:13am
424B5
g6k5fh54bjxohk57b
12 Jan 24
Prospectus supplement for primary offering
5:20pm
424B5
y4a8l81w9d4 orkcc
10 Jan 24
Prospectus supplement for primary offering
5:28pm
8-K
EX-99.1
99fk1 h3ws
7 Nov 23
Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2023 Financial Results
7:35am
8-K
EX-99.1
wx0msb8j69gl3j
9 Aug 23
Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2023 Financial Results
8:27am
424B5
rv2dl3p5 nxda
20 Jun 23
Prospectus supplement for primary offering
6:02am
424B5
dbq0vqlh
15 Jun 23
Prospectus supplement for primary offering
5:26pm
8-K
EX-99.1
g27c4
9 Nov 22
Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2022 Financial Results
4:03pm